Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. will announce interim three month data from its Phase 2b kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Monday, May 7th at 6:00 a.m. ET/4:00 a.m. MT. The management team will provide a review of the Phase 2b kidney transplant trial via a live conference call on Monday, May 7th ...
Copenhagen, Denmark (ots/PRNewswire) - - New Data Show Clear Benefit of Protelos(R) in Wide Range of Osteoporosis Patients Irrespective of Disease Severity New, long term data presented at the 34th European Symposium on Calcified Tissues (ECTS) this week underscore the unmatchable, long-term efficacy and ...
Calgary , Canada (ots/PRNewswire) - In the news release, "SemBioSys Announces First Quarter Results" issued on 3 May 2007 11:00 GMT, by SemBioSys Genetics Inc. TSX:SBS over PR Newswire, we are advised by a representative of the company that errors occurred in the headings of the financial tables. The comparative years were transposed by CNW in error. Complete corrected copy follows: - SemBioSys Announces First ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika today announced that the Company has been selected to give an oral presentation during the American Transplant Congress in San Francisco, California. An overview of the latest Phase 2b kidney transplant trial (PROMISE) results will be presented during an oral ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that the United States Patent and Trademark Office has awarded US Patent No. 7,205,337, which relates to the company's Reverse Phase Medium (RPM) carrier technology. The patent covers the use of IsoTis' current RPM technology in combination with various demineralized bone matrix (DBM) formulations, such as ...
Calgary , Canada (ots/PRNewswire) - - Canadian Biotechnology Company Achieves Insulin Milestones and Strengthens Balance Sheet SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing insulin and other metabolic and cardiovascular protein-based pharmaceuticals and a series of non-pharmaceutical products, today announced its operational and financial results for the 2007 first quarter which ...
Toronto (ots/PRNewswire) - "The Beijing 2008 Summer Olympics promises to be an historic event for the world of sports and for people worldwide," says Secretary-General Ban Ki-moon's Special Adviser on Sport for Development and Peace. Adolf Ogi has scheduled a meeting with Liu Qi, President of the Beijing ...
Evry, France (ots/PRNewswire) - The 2007 edition of the BIO (Biotechnology Industry Organization) trade show will be held in Boston (may 6-9). Genopole will attend this major event as part of a delegation coordinated by the Paris Il-de-France Regional Development Agency (ARD). Three innovative companies supported by Genopole(R) - Genewave, MATBiopharma and Vaxon ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Astellas announced today that the European Commission has approved the immunosuppressant Advagraf(R) (generic name: tacrolimus, prolonged release) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection ...
Basel, Switzerland (ots/PRNewswire) - - Newly published results show significant improvement in survival when innovative, oral cancer drug Tarceva is added to chemotherapy New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.(1) This survival ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has completed the transfer of the rights associated with its PolyActive technology to OctoPlus (Euronext: OCTO), a drug delivery and development company, in exchange for an up-front payment of approximately $1.7 million and future royalty payments on sales of pharmaceutical products based on the ...
Basel, Switzerland (ots/PRNewswire) - - Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once-monthly MIRCERA, a continuous erythropoietin receptor activator, effectively treats renal anaemia in one of the ...
Toronto, Canada (ots/PRNewswire) - - Vasogen to Host Conference Call Today at 9:00 a.m. (ET) Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic ...
Los Angeles (ots/PRNewswire) - - Awards Presented for Substantial Contributions to Cancer Research Innovative and collaborative cancer research can be the catalyst to improving patient outcomes. Celebrating the 100th anniversary of the American Association for Cancer Research (AACR) at the 2007 AACR Annual Meeting in Los Angeles, Eli Lilly and Company in ...
Irvine, California (ots/PRNewswire) - In the news release, "IsoTis Appoints James P. Abraham as Senior Vice President Sales" issued on 16 Apr 2007 12:00 GMT, by Isotis Inc nasdaq:ISOT over PR Newswire, we are advised by a representative of the company that the release is the same for several wire tasks, so the destinations will be added to this task transmitted by PR Newswire. Complete, corrected release follows: ...
Basel, Switzerland (ots/PRNewswire) - Nephrologists attending the upcoming World Congress of Nephrology (WCN) in Rio de Janeiro, Brazil 21-25 April will hear about a wide range of study results from Roche's robust renal anaemia clinical trial programs for its two treatments -- MIRCERA(R) and NeoRecormon(R). Among the highlights will be two analyses on MIRCERA, ...
Los Angeles (ots/PRNewswire) - - Lilly Oncology to present more than a dozen studies designed to better predict patient outcomes Delivering on its commitment to relentless progress in cancer care; Lilly Oncology will present 17 studies at the 2007 American Association for Cancer Research (AACR) Annual Meeting in Los Angeles from April 14-18, 2007. Many of ...
Barcelona, Spain (ots/PRNewswire) - - SEBIVO Suppressed Virus More Rapidly and Profoundly Than Adefovir(1) - Rapid and Powerful Viral Suppression Led to Better Treatment Outcomes(2) - SEBIVO Has Been Recommended for Approval by European Medicines Agency, Pending Final Approval by the European ...
Basel, Switzerland (ots/PRNewswire) - - High Response Rates Confirmed in 'Real-Life' Study and Clinical Trials BASEL, Switzerland, April 13 /PRNewswire/ -- Patients with hepatitis C who respond quickly to treatment have an excellent chance of being cured of the disease, according to data presented today ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika will host an evening educational symposium at the American Transplant Congress. The evening symposium titled "Unleashing the Power of CNi's" will take place on Saturday, May 5th at 7:30 p.m. at the San Francisco Marriott Hotel. The symposium will highlight the use of ISA247 for the prevention of transplant ...
Munich, Germany (ots/PRNewswire) - - The First Rapid Culture-Based Test With Results in Five Hours Clinicians attending the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) learned today that there is a new weapon available in the fight against Methicillin-resistant Staphyloccocus aureus (commonly referred to as MRSA). Hospitals fighting the battle to stop the spread of the ...
Basel, Switzerland (ots/PRNewswire) - - New Oral Treatment Option Reduces Time in Hospital by 80% - For Non-US Media Only The European Commission has approved Xeloda in combination with platinum-based chemotherapy, for first-line use in patients with advanced stomach cancer. Oral chemotherapy Xeloda, is already replacing standard intravenous (i.v.) ...
Edmonton (ots/PRNewswire) - - Company Set to Host Evening Symposium at ATC Isotechnika Inc. announced today that an independent data monitoring committee (DMC) has met and reviewed the interim data from the Phase 2b kidney transplant (PROMISE) trial. The review included 3 month data from approximately ...
International Association of Labour Inspection
Toronto, Ontario (ots/PRNewswire) - - April 18 - 20, 2007 The international health and safety community will focus on Ontario, Canada's practices in health and safety when the International Association of Labour Inspectors (IALI) Conference 2007 lands, for the first time in North America, in Toronto from April 18 - 20, 2007. Partnering with the Ontario ...
London (ots/PRNewswire) - - METEOR Trial Shows CRESTOR Slowed Progression of Atherosclerosis in People at Low-Risk of Coronary Heart Disease (Framingham 10 Year Risk ...
Tokyo, Japan, Woodcliff Lake, New Jersey and Exton, Pennsylvania (ots/PRNewswire) - - Eisai's Dramatic Leap Towards Biologic Therapeutics Evidenced by the Acquisition Eisai Co., Ltd. (Tokyo, "Eisai", President and CEO: Haruo Naito), Eisai Corporation of North America (Woodcliff Lake, NJ, "ECA", President: Hajime Shimizu) and Morphotek(R) Inc. (Exton, PA, "Morphotek", CEO: Nicholas Nicolaides) today announce that ECA has signed a definitive agreement to acquire ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Madrid (ots/PRNewswire) - - New Survey Indicates There is Room for Improvement in Physical Health Management Strategies for People Living With Schizophrenia New data presented at the 15th European Congress of Psychiatry (AEP) indicates that the impact of weight gain and metabolic abnormalities associated ...
London (ots/PRNewswire) - AstraZeneca today announced SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release) clinical trial data presented at the European Congress of Psychiatry (ECP) in Madrid. The data demonstrated that the SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release), administered once daily, ...
Carlsbad, California (ots/PRNewswire) - - Start of Phase 1 Clinical Trial Planned for the Second Half of This Year Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development of novel and proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, and ...
Carlsbad, California (ots/PRNewswire) - Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2006. As a ...